Ocular Therapeutix Stock News

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix (NASDAQ:OCUL) on Monday, setting a price target of $10, which is approximately 67.50% above the present share price of $5.

Good morning, everyone, and thank you for joining us on our first-quarter 2020 financial results and business update conference call. This morning, before the open, we issued a press release providin

Q1 2020 Ocular Therapeutix Inc Earnings Call

Shares of Ocular Therapeutix (NASDAQ:OCUL) were unchanged in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were up 8.89% year over year to ($0.41), whic

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -2.50% and -1.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 7) • Acceleron Pharma Inc (...

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t

Ocular Therapeutix (NASDAQ:OCUL) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, BidA

Broadwind Energy (NASDAQ:BWEN) +60%. on $19M order.TrovaGene (NASDAQ:TROV) +44% on new positive results from its ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avast

Gainers Document Security Systems, Inc. (NYSE: DSS) shares rose 43.8% to $0.43 in pre-market trading after the company reported completion of required independent valuation,...

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t